*Refresh the page if the below document does not appear.
Blackstone & Advent in discussions to acquire stake in Suven Pharma
Blackstone and Advent International, two private equity firms, are in separate negotiations to acquire a majority interest with Suven Pharmaceuticals Ltd. Advent has been buying pharma companies for the past two years, but this is Blackstone’s first effort to buy a pharma company.
IAG Cargo anticipates rising India pharma exports to UK & Europe
Senior officials from London-based IAG Cargo visited India last month to further examine prospects in air cargo transport between the two nations and with Europe, with pharma product air transport being a significant focus area, in the midst of ongoing government-togovernment negotiations.
Alembic's Ketorolac tromethamine injectable USP approved by USFDA
Alembic Pharmaceuticals Limited announced today that it has gained final FDA approval for its Abbreviated New Drug Application (ANDA) for Ketorolac Tromethamine Injection USP, 15 mg/mL, 30 mg/mL, and 60 mg/2 mL (30 mg/mL) Single Dose Vials.
Lupin receives warning letter from USFDA for its API plant in Maharashtra
US Food and Drug Administration has cited Lupin for manufacturing flaws, including the inability to establish proper documented procedures for cleaning equipment at its Maharashtra-based plant, which produces Active Pharmaceutical Ingredients (APIs).
Atorvastatin and bempedoic acid retail price fixation advised by NPPA panel
National Pharmaceutical Pricing Authority (NPPA) expert panel has recommended that Zydus Healthcare and Sun Pharma Laboratories fix their retail prices for lipid-lowering combo medications including atorvastatin and bempedoic acid.
e-Pharma market is expected to reach USD 142.7 billion by 2028
According to the report “e-Pharma Market by Application- Global Forecast to 2028, ” the market is expected to increase from USD 50.2 billion in 2021 to USD 142.7 billion by 2028. With its growing reliance on e-commerce platforms, the pharmaceutical industry is now driving market expansion.
Apellis Pharma's eye disease treatment delayed in order for FDA to analyse further clinical data
Apellis Pharmaceuticals announced that the
FDA’s approval of its experimental treatment
for geographic atrophy, a chronic eye disease
that is a primary cause of blindness in the
elderly, may be delayed due to the submission
of new clinical data.